Lipid Panel with Lp(a)

About one in five people worldwide carry a genetic version of a sticky cholesterol particle that quietly damages arteries and heart valves for decades, and most of them have no idea. A standard lipid panel will not catch it. Your LDL can look fine, your HDL can look great, and this number can still be flagging a level of cardiovascular risk that rivals familial high cholesterol.

The good news is that this is a one-and-done measurement for most adults: your level is roughly 90 percent inherited and stays remarkably stable across your life. Knowing it once tells you whether you carry a hidden, lifelong driver of heart disease, and it should change how aggressively you manage every other risk factor you actually can move.

What This Test Actually Measures

Lp(a) (lipoprotein little a) is a particle that looks a lot like LDL cholesterol, the so-called bad cholesterol, but with one extra protein stuck to it called apolipoprotein(a). That extra protein is what makes it dangerous. It promotes plaque buildup in artery walls, drives inflammation, and interferes with the body's ability to break down blood clots. Three problems for the price of one particle.

This test reports your concentration in nanomoles per liter (nmol/L), a unit for very small amounts of particles. Some labs still report in milligrams per deciliter (mg/dL), but the two units are not interchangeable, and there is no clean conversion factor that experts agree on. Always compare results from the same lab using the same units.

Heart Attack and Coronary Disease Risk

The relationship between Lp(a) and heart disease is not a simple yes or no. It is a continuous gradient: the higher your level, the higher your lifetime risk of a heart attack. There is no clean threshold below which you are completely safe, but there are pragmatic cutoffs that researchers use to flag elevated risk.

In Danish population data covering tens of thousands of adults, people with the very highest Lp(a) levels had roughly two to three times the risk of heart attack compared to those with the lowest levels. In a large meta-analysis pooled across European and North American cohorts, people with elevated LDL plus elevated Lp(a) had the worst outcomes, with about 8.86 percent developing cardiovascular events compared to lower rates when only one or neither was elevated. Each 50 nmol/L increment in Lp(a) raises the risk of atherosclerotic cardiovascular disease by roughly 11 percent.

What this means for you: if your Lp(a) is high, you cannot lower it much through diet or exercise, but you can dramatically reduce your overall cardiovascular risk by being aggressive about everything else you can control: LDL, blood pressure, smoking, blood sugar, and weight. The current treatment guidelines recommend pushing LDL below 70 mg/dL, and ideally lower, in people with elevated Lp(a) and any other risk factors.

Aortic Valve Stenosis

This is the association most people, including many doctors, have never heard about. Lp(a) is one of the only known causal drivers of calcific aortic valve stenosis, a progressive narrowing of the heart's main outflow valve that often ends in surgical replacement. Until recently, this disease was considered a wear-and-tear problem of aging. Genetic studies changed that picture.

In a long-term study of 77,680 Danish adults followed for up to 20 years, people with Lp(a) levels above 90 mg/dL (the top 5 percent of the population) had about 2.9 times the risk of developing aortic valve stenosis compared to those with the lowest levels. A genetic analysis published in the New England Journal of Medicine estimated about a 68 percent higher risk of aortic stenosis per copy of an Lp(a)-raising gene variant, and the European population EPIC-Norfolk study found that people in the top third of Lp(a) had about a 57 percent higher risk than those in the bottom third.

What this means for you: an elevated Lp(a) result is one of the only early warning signs that your aortic valve may calcify decades from now. There is no proven medical therapy yet to slow this process, but knowing your risk lets you push for earlier echocardiogram screening if a heart murmur develops, and it puts you near the front of the line for the first specific Lp(a)-lowering drugs that may become available in the coming years.

Stroke and Peripheral Artery Disease

The link between Lp(a) and ischemic stroke (a stroke caused by a blocked blood vessel) is real but weaker than for heart attack. A meta-analysis of 20 studies covering over 90,000 people found that those with the highest Lp(a) levels had about a 41 percent higher risk of ischemic stroke in case-control studies and about 29 percent higher in prospective studies. The signal is strongest in younger stroke patients, where high Lp(a) often shows up as the unexplained cause of an event in someone with no other obvious risk factors.

Lp(a) also tracks with peripheral artery disease, the narrowing of blood vessels in the legs. In UK Biobank data covering 460,544 adults followed for about 13.6 years, higher Lp(a) levels were independently linked to incident peripheral artery disease and carotid artery narrowing, with the highest-risk group concentrated above 150 nmol/L.

Reference Ranges

Risk runs on a continuum, so any single threshold is a pragmatic line in the sand rather than a true biological cliff. The most widely used cutoffs come from European and North American consensus groups, and they roughly agree on the territory below.

These tiers are drawn from published research. Your lab may use different assays and cutpoints, and the conversion between nmol/L and mg/dL is not exact. Compare your results within the same lab over time for the most meaningful trend.

One important nuance: these cutoffs were derived mostly from people of European ancestry. The distribution of Lp(a) varies by ancestry, and researchers are still working out whether thresholds should differ for people of African, South Asian, or East Asian descent. If you fall in a gray zone, your other risk factors matter more, not less.

Why One Reading Is Usually Enough (and Why You Should Still Recheck)

Lp(a) is unusual among cardiovascular markers in that your level is set almost entirely by your genes and stays roughly stable across your life once you reach early adulthood. For most people, a single accurate measurement gives you a result you can act on for decades. This is the opposite of LDL, which can swing dramatically with diet, weight, and medication.

That said, getting a baseline now and rechecking once is worth doing. Assays vary between labs, results near the gray zone deserve confirmation, and if Lp(a)-lowering therapies become approved in the next few years you will want a clean before-and-after picture. A reasonable approach: get your first measurement now, recheck once on the same assay if your value lands in or near the intermediate zone, and then leave it alone unless you start a therapy specifically targeting it. If you have a strong family history of early heart disease, also test your first-degree relatives, because high Lp(a) is inherited.

When Results Can Be Misleading

Lp(a) is more stable than most lipid markers, but a few things can throw off a single reading or make it harder to interpret.

• Acute illness or recent inflammation: Lp(a) behaves like an acute-phase reactant, meaning it can climb temporarily during a serious infection, after surgery, or after a heart attack. If you have been very sick in the last several weeks, retest later for a true baseline.
• Assay differences between labs: Different labs use different testing methods that can produce meaningfully different numbers for the same blood sample, particularly near decision thresholds. Always compare your trend within the same lab.
• Unit confusion: Some labs report in nmol/L and others in mg/dL, and there is no exact conversion. A number that looks reassuring in one unit may be alarming in the other.
• Pregnancy and severe kidney disease: Both can shift Lp(a) upward in ways that may not reflect your long-term baseline.